CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 409 filers reported holding CRISPR THERAPEUTICS AG in Q3 2023. The put-call ratio across all filers is 1.08 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $104,032 | -16.9% | 2,292 | +2.8% | 0.00% | – |
| Q2 2023 | $125,193 | +48.3% | 2,230 | +19.4% | 0.00% | – |
| Q1 2023 | $84,444 | +52.3% | 1,867 | +36.9% | 0.00% | – |
| Q4 2022 | $55,446 | -62.0% | 1,364 | -39.0% | 0.00% | – |
| Q3 2022 | $146,000 | +160.7% | 2,237 | +142.9% | 0.00% | – |
| Q2 2022 | $56,000 | +80.6% | 921 | +86.8% | 0.00% | – |
| Q1 2022 | $31,000 | -47.5% | 493 | -36.6% | 0.00% | – |
| Q4 2021 | $59,000 | -32.2% | 778 | 0.0% | 0.00% | – |
| Q3 2021 | $87,000 | -37.4% | 778 | -9.1% | 0.00% | – |
| Q2 2021 | $139,000 | +247.5% | 856 | +163.4% | 0.00% | – |
| Q1 2021 | $40,000 | +400.0% | 325 | +550.0% | 0.00% | – |
| Q4 2020 | $8,000 | +60.0% | 50 | -13.8% | 0.00% | – |
| Q3 2020 | $5,000 | – | 58 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $32,581,000 | 55.55% |
| NEA Management Company, LLC | 1,590,002 | $103,907,000 | 5.19% |
| ARK Investment Management | 8,237,122 | $538,296,000 | 3.75% |
| Nikko Asset Management Americas, Inc. | 4,262,736 | $277,078,000 | 3.54% |
| CLOUGH CAPITAL PARTNERS L P | 414,767 | $27,105,000 | 2.89% |
| Integral Health Asset Management, LLC | 220,000 | $14,377,000 | 2.79% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,268,000 | 2.48% |
| HC Advisors, LLC | 53,944 | $3,525,000 | 2.43% |
| Green Alpha Advisors, LLC | 27,466 | $1,795,000 | 1.52% |
| EFG Asset Management (North America) Corp. | 84,356 | $5,516,000 | 1.28% |